Ulcerative colitis is a chronic inflammatory bowel disease of unknown cause.
Symptoms include abdominal pain, diarrhea, blood in stool, fever, weight loss and anemia. Standard treatment includes anti-inflammatory, immunosuppressive and biological drugs.
For patients not responding to medical therapy, surgical removal of the large intestine is often the only remaining treatment option.Learn more
Kappaproct is a potential new medication for patients with moderate to severe ulcerative colitis.
Kappaproct is a first in class treatment that provides a local anti-inflammatory effect which in a phase III trial has shown to result in significant improvements on the major clinical symptoms.
Kappaproct has very limited systemic absorption. This gives the drug a favorable safety profile, in sharp contrast to many approved treatments.Learn more